Processa Pharmaceuticals, Inc. (PCSA): who owns it and who trades it
As of Nov 16, 2026, PCSA insiders reported 42 purchases worth $209K in the last 12 months. The largest buyer was Russell Skibsted (CFO), with $41.7K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Processa Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, PCSA insiders reported $209K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | George K Ng | CEO | Purchase | 3,057 | $1.93 | $5.9K | Form 4 |
| Jun 30, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 2,436 | $1.93 | $4.7K | Form 4 |
| Jun 30, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 2,106 | $1.93 | $4.1K | Form 4 |
| Jun 30, 2026 | Russell Skibsted | CFO | Purchase | 3,277 | $1.93 | $6.3K | Form 4 |
| Jun 30, 2026 | David Young | Director | Purchase | 2,531 | $1.93 | $4.9K | Form 4 |
| Jun 15, 2026 | David Young | Director | Purchase | 2,067 | $2.22 | $4.6K | Form 4 |
| Jun 15, 2026 | Russell Skibsted | CFO | Purchase | 2,654 | $2.22 | $5.9K | Form 4 |
| Jun 15, 2026 | George K Ng | CEO | Purchase | 2,465 | $2.22 | $5.5K | Form 4 |
| Jun 15, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,831 | $2.22 | $4.1K | Form 4 |
| Jun 15, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 2,118 | $2.22 | $4.7K | Form 4 |
| May 29, 2026 | David Young | Director | Purchase | 1,786 | $2.57 | $4.6K | Form 4 |
| May 29, 2026 | Russell Skibsted | CFO | Purchase | 2,292 | $2.57 | $5.9K | Form 4 |
| May 29, 2026 | George K Ng | CEO | Purchase | 2,129 | $2.57 | $5.5K | Form 4 |
| May 29, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,582 | $2.57 | $4.1K | Form 4 |
| May 29, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 1,829 | $2.57 | $4.7K | Form 4 |
| May 15, 2026 | George K Ng | CEO | Purchase | 1,843 | $2.97 | $5.5K | Form 4 |
| May 15, 2026 | David Young | Director | Purchase | 1,545 | $2.97 | $4.6K | Form 4 |
| May 15, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,369 | $2.97 | $4.1K | Form 4 |
| May 15, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 1,583 | $2.97 | $4.7K | Form 4 |
| May 15, 2026 | Russell Skibsted | CFO | Purchase | 1,984 | $2.97 | $5.9K | Form 4 |
| Apr 30, 2026 | Sian Bigora | Chief Development Office | Purchase | 1,971 | $2.71 | $5.3K | Form 4 |
| Apr 30, 2026 | David Young | Director | Purchase | 1,706 | $2.69 | $4.6K | Form 4 |
| Apr 30, 2026 | Russell Skibsted | CFO | Purchase | 2,190 | $2.69 | $5.9K | Form 4 |
| Apr 30, 2026 | George K Ng | CEO | Purchase | 2,034 | $2.69 | $5.5K | Form 4 |
| Apr 30, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,511 | $2.69 | $4.1K | Form 4 |
| Apr 30, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 1,748 | $2.69 | $4.7K | Form 4 |
| Apr 30, 2026 | Sian Bigora | Chief Development Office | Purchase | 1,986 | $2.69 | $5.3K | Form 4 |
| Apr 15, 2026 | George K Ng | CEO | Purchase | 1,843 | $2.97 | $5.5K | Form 4 |
| Apr 15, 2026 | David Young | Director | Purchase | 1,545 | $2.97 | $4.6K | Form 4 |
| Apr 15, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,369 | $2.97 | $4.1K | Form 4 |
| Apr 15, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 1,583 | $2.97 | $4.7K | Form 4 |
| Apr 15, 2026 | Sian Bigora | Chief Development Office | Purchase | 1,799 | $2.97 | $5.3K | Form 4 |
| Apr 15, 2026 | Russell Skibsted | CFO | Purchase | 1,984 | $2.97 | $5.9K | Form 4 |
| Mar 31, 2026 | George K Ng | CEO | Purchase | 2,136 | $2.54 | $5.4K | Form 4 |
| Mar 31, 2026 | James R Neal | Director | Purchase | 789 | $2.54 | $2K | Form 4 |
| Mar 31, 2026 | David Young | Director | Purchase | 1,810 | $2.54 | $4.6K | Form 4 |
| Mar 31, 2026 | Russell Skibsted | CFO | Purchase | 2,324 | $2.54 | $5.9K | Form 4 |
| Mar 31, 2026 | Geraldine Pannu | Director | Purchase | 2,072 | $2.54 | $5.3K | Form 4 |
| Mar 31, 2026 | Patrick Lin | Chief Business - Strateg | Purchase | 1,603 | $2.54 | $4.1K | Form 4 |
| Mar 31, 2026 | Wendy Guy | Chief Administrative Off | Purchase | 1,854 | $2.54 | $4.7K | Form 4 |
| Mar 31, 2026 | Sian Bigora | Chief Development Office | Purchase | 2,107 | $2.54 | $5.4K | Form 4 |
| Mar 31, 2026 | Khoso Baluch | Director | Purchase | 2,269 | $2.54 | $5.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Russell Skibsted | Chief Financial Officer | $41.7K | – | Jun 30, 2026 |
| George K Ng | Chief Executive Officer, Director | $38.7K | – | Jul 1, 2026 |
| Wendy Guy | Chief Administrative Officer | $32.9K | – | Jun 30, 2026 |
| David Young | Pres. Research & Development, Director | $32.4K | – | Jun 30, 2026 |
| Patrick Lin | Chief Business - Strategy Off | $28.5K | – | Jun 30, 2026 |
| Sian Bigora | Chief Development Officer | $21.4K | – | Apr 30, 2026 |
| Khoso Baluch | Director | $5.8K | – | Mar 31, 2026 |
| Geraldine Pannu | Director | $5.3K | – | Mar 31, 2026 |
| James R Neal | Director | $2K | – | Mar 31, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PCSA short interest
Low short interest. 0.9% of PCSA shares are sold short: about 1 share in 107. Over the last 12 reports the number of shares short went down 78%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 26,138 PCSA shares were sold short, 0.9% of the shares outstanding, down 43.8% from the report before. At the average daily volume of 27,704 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 26,138 | 0.94% | -44% | 27,704 | 1.0 |
| Oct 15, 2026 | 46,488 | 1.66% | +1023% | 329,090 | 1.0 |
| Sep 30, 2026 | 4,140 | 0.15% | -72% | 23,095 | 1.0 |
| Sep 15, 2026 | 14,995 | 0.54% | -58% | 29,028 | 1.0 |
| Aug 31, 2026 | 35,949 | 1.29% | -47% | 35,705 | 1.0 |
| Aug 14, 2026 | 67,319 | 2.41% | -69% | 78,571 | 1.0 |
| Jul 31, 2026 | 215,851 | 8.11% | +108% | 953,671 | 1.0 |
| Jul 15, 2026 | 103,554 | 3.89% | +20% | 74,139 | 1.4 |
| Jun 30, 2026 | 86,054 | 3.24% | -4% | 43,464 | 2.0 |
| Jun 15, 2026 | 89,983 | 3.38% | -1% | 78,796 | 1.1 |
| May 29, 2026 | 91,063 | 3.42% | -22% | 56,774 | 1.6 |
| May 15, 2026 | 116,594 | 4.38% | -14% | 60,842 | 1.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Processa Pharmaceuticals company events
Processa Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementProcessa Pharmaceuticals, Inc. issued a letter to the Company’s stockholders. Filing
- Nov 4, 2026LeadershipThe Board approved the appointment of Gregory J. Flesher as Chief Operating Officer of the Company, effective November 4, 2026. Filing
- Oct 29, 2026AnnouncementJustin Yorke resigned as chair of the board of directors of Processa Pharmaceuticals, Inc., and on October 28, 2026, the Board appointed Dr. Sheila Gujrathi as the non-employee executive chair of the Board, effective immediately. Filing
- Oct 5, 2026AnnouncementAmended an earlier report. The information set forth in the “Business Section of the Company” reflecting the business of the Company following the acquisition of Vidya is attached hereto as Exhibit 99.3 and incorporated herein by reference. Filing
- Aug 4, 2026LeadershipProcessa Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders. Filing
- Jul 29, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on July 28, 2026, effective immediately after the First Effective Time, Sheila Gujrathi was appointed to the Board as a director. Filing
- Apr 30, 2026LeadershipProcessa Pharmaceuticals, Inc. approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement. Filing
- Feb 19, 2026AgreementEnded an important agreement. Filing
- Jan 7, 2026AnnouncementProcessa Pharmaceuticals, Inc. received written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nastadq Capital Market pursuant to NASDAQ… Filing
- Dec 15, 2025SharesChanged the rights of its shareholders. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Processa Pharmaceuticals financials
Famous investors that hold PCSA
2 of the 50 well-known investors we track reported holding PCSA in their latest 13F filing. The largest position is Israel Englander's, worth $2.4M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1,875 | $2.4M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 58,629 | $96.2K | 0.0% | +175% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Processa Pharmaceuticals, Inc. (PCSA) stock
Are PCSA insiders buying or selling?
In the last 12 months, PCSA insiders reported 42 open-market purchases worth $209K and no sales. The latest trade was on Jul 1, 2026. See every trade.
What is the short interest in PCSA?
As of Oct 30, 2026, 26,138 PCSA shares were sold short, 0.9% of the shares outstanding, down 43.8% from the report before. At the average daily volume of 27,704 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold PCSA?
2 of the 50 well-known investors we track reported PCSA in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.4M. See all holders.
Executive pay
Processa Pharmaceuticals's chief executive was paid a total of $673K for the year ended Dec 31, 2025, up 29% from $521K the year before. In the last 12 months, Processa Pharmaceuticals's executives and directors bought $209K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.